Results 81 to 90 of about 113,040 (310)

Vehicular Ad hoc Network

open access: yes, 2013
{"references": ["Saleh Yousefi, Saeed Bastani, Mahmood Fathy, \"On the Performance of Safety Message Dissemination in Vehicular Ad Hoc Networks\", IEEE Fourth European Conference on Universal Multiservice Networks, European, 2007.", "Corson, Macker, \"Informational RFC 2501 MANET Performance Issues\", January 1999.", "C2C-CC: CAR 2 CAR Communication ...
openaire   +2 more sources

Epilepsy‐Associated Variants of a Single SCN1A Codon Exhibit Divergent Functional Properties

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Pathogenic variants in SCN1A, which encodes the voltage‐gated sodium channel NaV1.1, are associated with multiple epilepsy syndromes exhibiting a range of clinical severity. SCN1A variants are reported in different syndromes, including Dravet syndrome, which is associated with loss‐of‐function, whereas neonatal/infantile‐onset ...
Lanie N. Liebovitz   +3 more
wiley   +1 more source

Energy efficiency in ad-hoc wireless networks [PDF]

open access: yes, 2010
In ad-hoc wireless networks, nodes are typically battery-powered, therefore energy limitations are among the critical constraints in ad-hoc wireless networks' development. The approaches investigated in this thesis to achieve energy efficient performance
Feng, Wei
core  

A cluster-head selection and update algorithm for ad hoc networks [PDF]

open access: yes, 2010
A novel cluster-head selection and update algorithm “Type-based Cluster-forming Algorithm (TCA)” is proposed, which outperforms both the lowest node ID (LID) and the Weighted Clustering Algorithm (WCA) in the ad hoc network scenario considered.
Zhangdui Zhong   +5 more
core   +1 more source

Multidimensional Profiling of MRI‐Negative Temporal Lobe Epilepsy Uncovers Distinct Phenotypes

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Although hippocampal sclerosis (TLE‐HS) represents the most frequent cause of temporal lobe epilepsy (TLE), up to 30% of patients show no lesion on visual MRI inspection (TLE‐MRIneg). These cases pose diagnostic and therapeutic challenges and are underrepresented in surgical series.
Alice Ballerini   +28 more
wiley   +1 more source

Cognitive routing for wireless ad hoc networks [PDF]

open access: yes, 2011
This thesis examines the design of cognitive routing to improve wireless ad hoc network performance in terms of throughput and delay, as well as reducing the impact of relaying on the network, without deteriorating end-to-end capacity.
Han, Bo
core  

An efficient counter-based broadcast scheme for mobile ad hoc networks [PDF]

open access: yes, 2007
In mobile ad hoc networks (MANETs), broadcasting plays a fundamental role, diffusing a message from a given source node to all the other nodes in the network.
Ould-Khaoua, M.   +2 more
core   +1 more source

Geometric aspects of probabilistic broadcasting in ad hoc networks [PDF]

open access: yes, 2020
This paper studies pure probabilistic broadcast in ad hoc networks under a variety of topological scenarios, offering a comparison of the performance of broadcast in lattice-like geometric node layouts (e.g.
Peña T., Néstor M.   +2 more
core   +1 more source

A survey of performance enhancement of transmission control protocol (TCP) in wireless ad hoc networks

open access: yesEURASIP Journal on Wireless Communications and Networking, 2011
Transmission control protocol (TCP), which provides reliable end-to-end data delivery, performs well in traditional wired network environments, while in wireless ad hoc networks, it does not perform well.
Mast Noor, Owens Thomas
doaj  

Onasemnogene Abeparvovec in Type I Spinal Muscular Atrophy: 24‐Month Follow‐Up From the Italian Registry

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Onasemnogene abeparvovec (OA) is an AAV9‐based gene therapy for spinal muscular atrophy type I (SMA I). Real‐world outcomes show increased response variability compared to clinical trials, and follow‐up data beyond 12–18 months are limited.
Marika Pane   +43 more
wiley   +1 more source

Home - About - Disclaimer - Privacy